CD274 and glioblastoma: In glioblastoma (GBM), using dual-sgRNA CRISPR/Cas9 technology to remove both surface and intracellular PD-L1 from human U87 GBM cells resulted in a 64% PD-L1 reduction, significantly decreased cell migration, and promoted pro-inflammatory macrophage polarization.